Cargando…

Remodeling of the tumor/tumor microenvironment ecosystem during KRAS G12C inhibitor clinical resistance in lung cancer

KRAS G12C inhibitors such as sotorasib and adagrasib are often effective in KRAS G12C–driven non–small cell lung cancer (NSCLC) patients. However, acquired resistance limits long-term patient survival. In this issue of the JCI, Tsai et al. present a comprehensive genetic analysis of multiple tumors...

Descripción completa

Detalles Bibliográficos
Autores principales:	Manabe, Tadashi, Bivona, Trever G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Clinical Investigation 2022
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8843703/ https://www.ncbi.nlm.nih.gov/pubmed/35166243 http://dx.doi.org/10.1172/JCI156891

Ejemplares similares

SHP2 inhibition diminishes KRAS(G12C) cycling and promotes tumor microenvironment remodeling
por: Fedele, Carmine, et al.
Publicado: (2020)

Intracranial responses with selective KRAS-G12C inhibitors in non-small cell lung cancer
por: Lu, Kevin, et al.
Publicado: (2023)

Critical requirement of SOS1 for tumor development and microenvironment modulation in KRAS(G12D)-driven lung adenocarcinoma
por: Baltanás, Fernando C., et al.
Publicado: (2023)

Mechanisms of Resistance to KRAS(G12C) Inhibitors
por: Dunnett-Kane, Victoria, et al.
Publicado: (2021)

Bispecific T cell engagers kill resistant cells during KRAS-G12C blockade therapy
por: Song, Xinxin, et al.
Publicado: (2022)

Key roles of EMT for adaptive resistance to MEK inhibitor in KRAS mutant lung cancer
por: Kitai, Hidenori, et al.
Publicado: (2016)

Resistance is futile: overcoming resistance to targeted therapies in lung adenocarcinoma
por: Neel, Dana S., et al.
Publicado: (2017)

Resistance to KRAS(G12C) Inhibitors in Non-Small Cell Lung Cancer
por: Blaquier, Juan Bautista, et al.
Publicado: (2021)

KRAS mutant colorectal tumors: Past and present
por: Brand, Toni M., et al.
Publicado: (2012)

Mechanisms of Resistance to Epidermal Growth Factor Receptor Inhibitors and Novel Therapeutic Strategies to Overcome Resistance in NSCLC Patients
por: Lin, Luping, et al.
Publicado: (2012)

CodeBreak 200: Sotorasib Has Not Broken the KRAS(G12C) Enigma Code
por: Zhang, Shannon S, et al.
Publicado: (2023)

Evaluation of KRAS(G12C) inhibitor responses in novel murine KRAS(G12C) lung cancer cell line models
por: Sisler, Daniel J., et al.
Publicado: (2023)

KRAS inhibitors: going noncovalent
por: Drosten, Matthias, et al.
Publicado: (2022)

Differences in gynecologic tumor development in Amhr2-Cre mice with KRAS(G12D) or KRAS(G12V) mutations
por: Kun, Eucharist H. S., et al.
Publicado: (2020)

Frequency of KRAS p.Gly12Cys Mutation in Brazilian Patients With Lung Cancer
por: Cavagna, Rodrigo, et al.
Publicado: (2021)

Targeting the Tumor Microenvironment: An Unexplored Strategy for Mutant KRAS Tumors
por: Dias Carvalho, Patrícia, et al.
Publicado: (2019)

Targeting KRAS in Lung Cancer Beyond KRAS G12C Inhibitors: The Immune Regulatory Role of KRAS and Novel Therapeutic Strategies
por: Cucurull, Marc, et al.
Publicado: (2022)

Rapid acceleration of KRAS-mutant pancreatic carcinogenesis via remodeling of tumor immune microenvironment by PPARδ
por: Liu, Yi, et al.
Publicado: (2022)

Combined KRAS(G12C) and SOS1 inhibition enhances and extends the anti-tumor response in KRAS(G12C)-driven cancers by addressing intrinsic and acquired resistance
por: Thatikonda, Venu, et al.
Publicado: (2023)

Anticancer Efficacy of KRAS(G12C) Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of KRAS(G12C)-Mutant Pancreatic and Lung Cancers
por: Khan, Husain Yar, et al.
Publicado: (2023)

Thrombospondins and remodeling of the tumor microenvironment
por: Stenina-Adognravi, Olga, et al.
Publicado: (2018)

TEAD Inhibitors Sensitize KRAS(G12C) Inhibitors via Dual Cell Cycle Arrest in KRAS(G12C)-Mutant NSCLC
por: Tammaccaro, Salvina Laura, et al.
Publicado: (2023)

Role of endothelial cells in tumor microenvironment
por: Yang, Dawei, et al.
Publicado: (2021)

Finding the right help in the tumor microenvironment
por: Filderman, Jessica N., et al.
Publicado: (2022)

Direct GDP-KRAS(G12C) inhibitors and mechanisms of resistance: the tip of the iceberg
por: Rosen, Joshua C., et al.
Publicado: (2023)

EGFR targeted therapy resistance: current status, challenges, and future outlook
por: Bivona, Trever G.
Publicado: (2020)

KRAS(G12C)-independent feedback activation of wild-type RAS constrains KRAS(G12C) inhibitor efficacy
por: Ryan, Meagan B., et al.
Publicado: (2022)

Highlights: Lymphoma microenvironment: Current progress of the tumor microenvironment in lymphoid malignancies
por: Karube, Kennosuke
Publicado: (2021)

CodeBreaK 200: Sotorasib (AMG510) Has Broken the KRAS G12C+ NSCLC Enigma Code
por: Brazel, Danielle, et al.
Publicado: (2023)

Acquired resistance to KRAS G12C small-molecule inhibitors via genetic/nongenetic mechanisms in lung cancer
por: Mohanty, Atish, et al.
Publicado: (2023)

A saturation mutagenesis screen uncovers resistant and sensitizing secondary KRAS mutations to clinical KRAS(G12C) inhibitors
por: Feng, Siyu, et al.
Publicado: (2022)

Remodeling tumor microenvironment with natural products to overcome drug resistance
por: Zhang, Wanlu, et al.
Publicado: (2022)

Identification of KRAS(G12C) Mutations in Circulating Tumor DNA in Patients With Cancer
por: Thein, Kyaw Z., et al.
Publicado: (2022)

Tumor Immune Microenvironment and Immunotherapy in Non-Small Cell Lung Cancer: Update and New Challenges
por: Xing, Shuqin, et al.
Publicado: (2022)

KRAS as a Modulator of the Inflammatory Tumor Microenvironment: Therapeutic Implications
por: Pereira, Flávia, et al.
Publicado: (2022)

EHMT2 methyltransferase governs cell identity in the lung and is required for KRAS (G12D) tumor development and propagation
por: Pribluda, Ariel, et al.
Publicado: (2022)

Therapeutic Injury and Tumor Regrowth: Tumor Resection and Radiation Establish the Recurrent Glioblastoma Microenvironment
por: Silver, Daniel J., et al.
Publicado: (2018)

The Research Progress of Direct KRAS G12C Mutation Inhibitors
por: Yang, Ai, et al.
Publicado: (2021)

Adaptive stress signaling in targeted therapy resistance in cancer
por: Pazarentzos, Evangelos, et al.
Publicado: (2015)

Reducing the immunosuppressive tumor microenvironment enhances photoimmunotherapy efficacy
por: Sioud, Mouldy
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ehln88q2p4dmj3126ujoiod8g2